COX2 overexpression is a prognostic marker for Stage III breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 1, 2012, Pages 51-59

  Kim, Hee Sung ^a   Moon, Hyeong Gon ^b   Han, Wonshik ^b   Yom, Cha Kyung ^b   Kim, Woo Ho ^b   Kim, Jun Ho ^c   Noh, Dong Young ^b  

^a Korea Electric Power Research Institute (KEPRI)   (South Korea)

^b Seoul National University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

COX2; Invasive breast cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857916954     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1521-3     Document Type: Article

References (33)

1. Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ (2007) Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96:575-582. doi:10.1038/sj.bjc.6603593
2. Mazhar D, Ang R, Waxman J (2006) COX inhibitors and breast cancer. Br J Cancer 94:346-350. doi:10.1038/sj.bjc.6602942 (Pubitemid 43237558)
3. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ (2001) Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8:97-114 (Pubitemid 32641352)
4. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632-635 (Pubitemid 34126931)
5. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97:2978-2987. doi:10.1002/cncr.11437 (Pubitemid 36676251)
6. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55:429-434 (Pubitemid 34620779)
7. O'Connor JK, Avent J, Lee RJ, Fischbach J, Gaffney DK (2004) Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 58:1034-1040. doi:10.1016/j.ijrobp.2003.08.032 (Pubitemid 38314783)
8. Park K, Han S, Shin E, Kim HJ, Kim JY (2006) Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 32:1093-1096. doi:10.1016/j.ejso. 2006.05.010 (Pubitemid 44774393)
9. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005-1009. doi:10.1038/nature08021
10. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A (2007) COX-2 involvement in breast cancer metastasis to bone. Oncogene 26:3789-3796. doi:10.1038/sj.onc.1210154 (Pubitemid 46878131)
11. Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-102. doi:10.1016/S0165-6147(02)00043-3 (Pubitemid 36135884)
12. Liu B, Qu L, Tao H (2010) Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance. Cell Biol Int 34:21-25. doi:10.1042/CBI20090129
13. Kalalinia F, Elahian F, Behravan J (2010) Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines. J Cancer Res Clin Oncol. doi:10.1007/s00432-010-0893-9
14. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA (2004) Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 10:4062-4067. doi:10.1158/1078-0432.CCR-03-0463 (Pubitemid 38812482)
15. Canney PA, Machin MA, Curto J (2006) A feasibility study of the efficacy and tolerability of the combination of exemestane with the COX-2 inhibitor celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer 42:2751-2756. doi:10.1016/j.ejca.2006.08.014 (Pubitemid 44584673)
16. Greene FL PD, Fleming ID (2002) AJCC Cancer Staging Manual. Springer, New York
17. Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, Park SY (2008) The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 61:317-321. doi:10.1136/jcp.2007.050336 (Pubitemid 351354237)
18. Park JY, Cho MO, Leonard S, Calder B, Mian IS, Kim WH, Wijnhoven S, van Steeg H, Mitchell J, van der Horst GT, Hoeijmakers J, Cohen P, Vijg J, Suh Y (2008) Homeostatic imbalance between apoptosis and cell renewal in the liver of premature aging Xpd mice. PLoS One 3:e2346. doi:10.1371/journal.pone.0002346
19. De Santis G, Miotti S, Mazzi M, Canevari S, Tomassetti A (2009) E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene 28:1206-1217. doi:10.1038/onc.2008.470
20. Marinari B, Moretti F, Botti E, Giustizieri ML, Descargues P, Giunta A, Stolfi C, Ballaro C, Papoutsaki M, Alema S, Monteleone G, Chimenti S, Karin M, CostanzoA(2008) The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway. Proc Natl Acad Sci USA 105:17091-17096. doi:10.1073/pnas.0809288105
21. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ, Bartlett JM (2011) COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125(3):671-685
22. Kostopoulos I, Arapantoni-Dadioti P, Gogas H, Papadopoulos S, Malamou-Mitsi V, Scopa CD, Markaki S, Karagianni E, Kyriakou V, Margariti A, Kyrkou E, Pavlakis K, Zaramboukas T, Skordalaki A, Bourli A, Markopoulos C, Pectasides D, Dimopoulos MA, Skarlos D, Fountzilas G (2006) Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat 96:251-261. doi:10.1007/s10549-005-9062-2
23. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P (2003) Correlation of COX- 2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88:574-578. doi:10.1038/sj.bjc.6600741 (Pubitemid 36363367)
24. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M (2009) Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117:61-68. doi:10.1007/s10549-008-0135-x
25. Haffty B, Yang Q, Moran M, Tan A, Reiss M (2008) Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 71:1006-1013. doi:10.1016/j.ijrobp.2007.11.063
26. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168-1176. doi:10.1200/JCO.2008.18.1024
27. Singh-Ranger G, Salhab M, Mokbel K (2008) The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109:189-198. doi:10.1007/s10549-007-9641-5
28. Kelly LM, Hill AD, Kennedy S, Connolly EM, Ramanath R, Teh S, Dijkstra B, Purcell R, McDermott EW, O'Higgins N (2003) Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29:707-710. doi:10.1016/j.ejso.2003.07.001 (Pubitemid 37483941)
29. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90:423-429. doi:10.1038/sj.bjc.6601534 (Pubitemid 38250640)
30. Mohammad AM, Abdel HA, Abdel W, Ahmed AM, Wael T, Eiman G (2006) Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy. Indian J Cancer 43:163-168
31. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ (2006) HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 66:5504-5511. doi:10.1158/0008-5472.CAN-05-4076 (Pubitemid 43844979)
32. Schmitz KJ, Callies R, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee HS, Takeda A, Schmid KW, Baba HA (2006) Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol 59:685-691. doi:10.1136/jcp.2005.030650 (Pubitemid 44048775)
33. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM (2004) Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45:47-54. doi:10.1111/j.1365-2559.2004.01898.x (Pubitemid 38969561)